Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2026

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Overview

• Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market size has reached to $13.97 billion in 2025 • Expected to grow to $17.86 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Rising Prevalence Of ADHD Spurs Growth In The Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutic Market • Market Trend: Leading Companies Innovate With Over-The-Counter (OTC) Digital Therapeutics For ADHD In The US Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD. The main types of drugs in attention deficit hyperactivity disorder (ADHD) therapeutics are stimulants and non-stimulants. Stimulants are medications that increase certain chemicals in the brain, helping improve attention and focus. It includes various psychotherapies, such as behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy, and is adapted for different age groups, including pediatric, adolescent, and adult, and distributed through hospital pharmacies, specialty clinics, retail pharmacies, and e-commerce.

What Is The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Forecast?

The attention deficit hyperactivity disorder (adhd) therapeutics market size is expected to see strong growth in the next few years. It will grow to $17.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to advancement in precision medicine for adhd, adoption of digital therapeutics, expansion of telehealth platforms, integration of ai in adhd management, increasing adult adhd diagnosis. Major trends in the forecast period include personalized adhd treatment programs, telehealth and remote adhd management, digital therapeutics and mobile apps for adhd, non-pharmacological interventions growth, integration of behavioral and cognitive therapies.

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segmentation

1) By Drug Type: Stimulants, Non-Stimulants 2) By Psychotherapy: Behavior Therapy, cognitive behavioral therapy, Family Therapy 3) By Age Group: Pediatric And Adolescent, Adult 4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies Subsegments: 1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants 2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

What Is The Driver Of The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

The increasing prevalence of attention-deficit hyperactivity disorder is expected to propel the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of attention-deficit hyperactivity disorder (ADHD) refers to the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHS therapeutics address the multifaceted nature of the condition, aiming to improve symptom management, functional impairment, quality of life, and overall well-being for individuals affected by ADHD. For instance, in May 2025, according to NHS England Digital, a UK-based national information and technology partner, in May 2025, an estimated 2,498,000 individuals in England are living with ADHD, including both diagnosed and undiagnosed cases. Therefore, the increasing prevalence of ADHD is driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.

Key Players In The Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Major companies operating in the attention deficit hyperactivity disorder (adhd) therapeutics market are Pfizer Inc, Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd, UCB S.A., Amneal Pharmaceuticals LLC, Lupin Limited, Mallinckrodt Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Tris Pharma Inc, NEOS Therapeutic Inc, Rhodes Pharmaceuticals L.P., KemPharm Inc, Ironshore Pharmaceuticals Inc, Purdue Pharma L.P., Aevi Genomic Medicine, Highland Therapeutics Inc

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends and Insights

Major companies operating in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing on the development of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD to meet increased demand for digital solutions and the rise in demand for remote healthcare. Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These interventions are designed to be used independently or with traditional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an over-the-counter (OTC) version of its video game-based digital therapeutic for adults with attention-deficit hyperactivity disorder (ADHD). The OTC version, EndeavorOTC, is designed to improve attention, time management, and organizational skills. Additionally, this move follows the success of Akili's FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version provides adults with a non-drug treatment option for managing ADHD symptoms.

What Are Latest Mergers And Acquisitions In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

In July 2024, Virtual Therapeutics Corp., a US-based digital health company, completed the acquisition of Akili, Inc., for an undisclosed amount. With this acquisition, Akili aims to combine its validated mobile digital therapeutics with Virtual Therapeutics' VR mental health solutions to create a leading digital health company delivering engaging, scalable games to improve mental health across multiple high-impact conditions. Akili, Inc. is a US-based digital therapeutics company that offers attention deficit hyperactivity disorder (ADHD) therapeutics.

Regional Insights

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

The attention deficit hyperactivity disorder (ADHD) therapeutic market consists of revenues earned by entities by providing services such as medication management, behavioral therapy, social skills training, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) therapeutic market also includes sales of medication, behavioral modification tools, organization and planning tools, and assistive technologies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2026?

The attention deficit hyperactivity disorder (adhd) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder (adhd) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.